| abstract |
Compositions and formulations or co-formulations containing hyaluronan degrading enzymes are provided. The composition, formulation or co-formulation may also contain other therapeutic agents suitable for the treatment of benign prostatic hypertrophy, such as, for example, 5-alpha reductase inhibitors. The compositions and formulations can be used for the treatment of benign prostatic hypertrophy. The compositions and formulations can be provided in combination with one or more other agents for the treatment of benign prostatic hypertrophy. |